Iron Mountain Inc vs uniQure N.V. Ordinary Shares — how do they compare? Iron Mountain Inc trades at $111.8 (market cap $33.00B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: Iron Mountain Inc is far larger — about 22.8× uniQure N.V. Ordinary Shares's market cap, and Iron Mountain Inc pays a 3.12% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| IRM | QURE | |
|---|---|---|
Market Cap | $33.00B | $1.45B |
Volume | 1,075,916 | 3,323,243 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $70.59 |
52-Week Low | $78.86 | $9.03 |
Typical Hold Time | 80 Days | 0 Days |
Enterprise Value | $52.41B | $707.46M |
Dividend Yield | 3.12% | — |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $114.60, down 0.43% on the day, with a neutral technical signal. The stock shows strong analyst support with a 66.7% buy rating and a consensus price target of $142.75, implying significant upside. Recent earnings have consistently beaten expectations, and the company is expanding its data center pipeline and digital solutions, as highlighted in recent news. However, high debt levels and a declining net income margin present fundamental concerns.
The outlook is mixed: growth in data centers and digital services offers opportunity, but elevated valuation ratios and leverage pose risks. Investor sentiment is cautiously optimistic, driven by strategic initiatives, though execution and macroeconomic factors remain key watchpoints for stock performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →